 Minerva Neurosciences Inc. NERV, 7.61 said Monday that it received a refusal to file letter from the Food and Drug Administration for its application for roluperidone as a treatment for patients with schizophrenia. The company intends to request a Type A meeting and looks forward to continued discussions with the FDA, Minerva CEO said in a news release. 